Robert Tepper
Gastroenterology · New Hyde Park, NYNPI 1023013570
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 147 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by AbbVie at 32.9% of the total. Reporting peaked in 2019 at $1,588 and has fallen 92.1% since, to $125 in 2024.
Across 147 payments — averaging $19.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$930
- Johnson & Johnson$367
- Takeda Pharmaceuticals U.S.A., Inc.$231
- Intercept Pharmaceuticals, Inc.$183
- Merck$172
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$158
- plus $781 from 12 others
Across 48 payments — averaging $2658.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$60K
- Amgen$27K
- Ironwood Pharmaceuticals, Inc$22K
- Redhill Biopharma Inc.$17K
- AbbVie$651
- Pfizer$488
What the payments were for
- Consulting fees$161%
- Food & beverage$2,80799%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 50 | $930 |
| Johnson & Johnson | 21 | $367 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $231 |
| Intercept Pharmaceuticals, Inc. | 11 | $183 |
| Merck | 12 | $172 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $158 |
| Pfizer | 7 | $128 |
| Ipsen Biopharmaceuticals, Inc | 1 | $125 |
| Esperion Therapeutics, Inc. | 1 | $125 |
| UCB, Inc. | 4 | $80 |
| Redhill Biopharma Inc. | 3 | $74 |
| Bristol Myers Squibb | 4 | $71 |
| Ferring Pharmaceuticals Inc. | 3 | $65 |
| Daiichi Sankyo Inc. | 2 | $37 |
| Braintree Laboratories, Inc. | 2 | $29 |
| Sanofi | 1 | $19 |
| Ardelyx, Inc. | 1 | $15 |
| Ironwood Pharmaceuticals, Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,823 in reported general payments places this provider in the 55th percentile of 1,682 gastroenterology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 44 | $1,147,338 |
| Humira(Cf) PenAdalimumab | 30 | $438,318 |
| CreonLipase/Protease/Amylase | 56 | $157,232 |
| LinzessLinaclotide | 125 | $89,786 |
| ViberziEluxadoline | 25 | $39,094 |
| XifaxanRifaximin | 14 | $32,950 |
| Mesalamine | 39 | $31,643 |
| ZenpepLipase/Protease/Amylase | 18 | $27,529 |
| Mesalamine ErMesalamine | 21 | $17,673 |
| Dexlansoprazole DrDexlansoprazole | 42 | $11,341 |
| Balsalazide Disodium | 39 | $9,120 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 108 | $6,679 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 34 | $5,825 |
| Pantoprazole Sodium | 383 | $5,550 |
| Lubiprostone | 21 | $3,984 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $367 | $1,147,33844 claims |
| AbbVieCreon, Linzess, Viberzi | $930 | $286,112206 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $158 | $32,95014 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $65 | $5,82534 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,682 gastroenterology providers in New York.
Other gastroenterology in New Hyde Park
- Ian StorchNew Hyde Park$166K
- David Carr LockeNew York$2M
- Arthur KornbluthNew York$1.9M
- Maya SrivastavaWilliamsville$1.8M
- Melissa PalmerPlainview$1M
- Sonal KumarNew York$1M
- David PoppersNew York$939K
- Ellen ScherlNew York$857K
- Bruce SandsNew York$810K
- Jean Frederick ColombelNew York$786K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.